Table 2.
Intra-articular hyaluronan therapy in knee osteoarthritis: summary of meta-analyses
| Reference | Lo27 | Wang29 | Arrich26 | Modawal28 | Bellamy25 |
|---|---|---|---|---|---|
| Total no. of studies | 22 | 20 | 22 | 11 | 76 |
| Efficacy outcome measures | Effect size (change from baseline pain vs placebo) | Mean difference, ASPID vs placebo | WMD in pain during/after exercise (VAS) vs control | VAS | WMD in pain on weight bearing vs placebo |
| Key pooled results | Effect size: 0.32 (P < 0.001) | Mean difference for ASPID: 13.4% | WMD 10–14 wk: −4.3 mm (P = 0.013) WMD 22–30 wk: −7.1 mm (P = 0.013) |
WMD 5–7 wk: 17.6 (95% CI, +7.5, +28.0) 8–12 wk: 18.1 (95% CI, +6.3, +29.9) 15–22 wk: 4.4 (95% CI, −15.3, 24.1) |
% Change 5–13 wk: +26% for pain; +23% for function |
| Conclusion | Small treatment effect | Safe and effective | Not effective in measured outcomes | Moderately effective at 5–10 wk, not effective at 15–22 wk | Effective treatment for pain, function, pt, global assessment at 5–13 wk |
Abbreviations: ASPID, adjusted sum of pain intensity differences; WMD, weighted mean difference; VAS, visual analog scale; pt, patient.